Recent News

• 03.25.2026 - Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
• 03.24.2026 - Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
• 03.23.2026 - Outlook Therapeutics Announces Proposed Public Offering
• 03.16.2026 - Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
• 03.05.2026 - Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
• 02.19.2026 - Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
• 02.17.2026 - Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Recent Filings

• 03.25.2026 - 8-K Current report
• 03.25.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.16.2026 - 8-K Current report
• 03.16.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 8-K Current report
• 03.11.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 8-K Current report
• 03.05.2026 - EX-99.1 EX-99.1
• 03.05.2026 - 8-K Current report